Abbreviated Name

PASS_MPS

Lead Investigator

Chinnaiyan, Arul M. — University of Michigan

Coordinating Investigator

No coordinating investigator

Involved Investigators

• Chinnaiyan, Arul M. — University of Michigan
• Lin UW, Daniel W. — University of Washington

Abstract

n/a

Aims

Primary Aim: Evaluation of an existing, urine-based molecular assay to predict progression, need for definitive therapy, or recurrence for men on active surveillance for PCa. By identifying molecular metabolites in post-DRE urine of men on active surveillance in Canary PASS that are specific for aggressive disease, we will 1) evaluate the discriminative ability of our existing MPS assay for prediction of progression (GG≥3 on re-biopsy or pathology) 2) need for definitive treatment 3) or recurrence after treatment. Exploratory Aim: Development of a novel, urine-based molecular assay to predict progression, need for definitive therapy, or recurrence for men on active surveillance for PCa. By identifying molecular metabolites in post-DRE urine of men on active surveillance in Canary PASS, we will 1) assess for opportunities for improving the existing assay and/or 2) perform de novo creation of a novel biomarker to predict progression or recurrence.

Analytic Method

No analytic method available.

Publications

• No publications available at this time for this protocol.

Biomarkers

• No biomarkers available at this time for this protocol.

Data Collections

• No data collections available at this time for this protocol.

Start Date

Feb 1 2023

Estimated Finish Date

Feb 1 2025

Protocol ID

512

Protocol Type

Collaboration

Fields of Research

• UNKNOWN

Collaborative Group

Prostate and Urologic Cancers Research Group

Cancer Types

• Malignant neoplasm of prostate